Miyazaki M, Makowka L, Falk R E, Falk J A, McDonell M, Venturi D
J Surg Res. 1983 May;34(5):415-26. doi: 10.1016/0022-4804(83)90090-2.
These studies further evaluate the hepatocytoprotective properties of 16,16-dimethyl prostaglandin E2 (dmPGE2) by assessing its effect on survival, liver function, and hepatic regeneration in a model of in vivo isolated perfusion of the rat liver with high concentrations of cytotoxic drugs and regional hyperthermia. Isolated perfusion with 1.0 g/kg of 5-FU or hyperthermia of 41 degrees C X 10 min resulted in 90-100% mortality in control rats, with extensive, patchy necrosis and infarction on histologic examination, and markedly elevated levels of SGOT and SGPT at 24 hr after perfusion. Pretreatment with dmPGE2 (10 micrograms/kg sc) at 30 min before, and at 6 and 24 hr after hepatic perfusion significantly improved survival to 80% (P less than 0.01) following 5-FU perfusion and to 40% (P less than 0.05) following hyperthermic perfusion. Animals were followed for at least 21 days after perfusion and demonstrated normal liver histology, dmPGE2-treated rats demonstrated significantly lower SGOT and SGPT levels at 24 hr after perfusion. dmPGE2 (2 micrograms/kg sc) given as above improved the length of time of survival but eventual mortality was not significantly improved. Oral administration (50 micrograms/kg po at 30 min before, 6 and 24 hr after perfusion) and posttreatment (10 micrograms/kg sc at 1, 6, and 24 hr after perfusion) had no significant effect on survival. Hepatic regenerative capacity following partial hepatectomy was severely suppressed following isolated hyperthermochemotherapeutic hepatic perfusion. Pretreatment with dmPGE2 (10 micrograms/kg sc) restored the DNA synthetic response in perfused rats to that seen in normal control rats after partial hepatectomy (P less than 0.05 and P less than 0.01). The results from these studies further confirm the role of dmPGE2 as a hepatocytoprotective agent and suggest potential clinical application in situations where there has been deliberate, therapeutic insult to the liver.
这些研究通过评估16,16 - 二甲基前列腺素E2(dmPGE2)在高浓度细胞毒性药物和局部热疗的大鼠肝脏体内分离灌注模型中对存活、肝功能和肝再生的影响,进一步评价其肝细胞保护特性。用1.0 g/kg的5 - 氟尿嘧啶(5 - FU)进行分离灌注或41℃×10分钟的热疗导致对照大鼠死亡率达90 - 100%,组织学检查显示广泛、散在的坏死和梗死,灌注后24小时血清谷草转氨酶(SGOT)和谷丙转氨酶(SGPT)水平显著升高。在肝脏灌注前30分钟以及灌注后6小时和24小时,用dmPGE2(10微克/千克,皮下注射)预处理,可使5 - FU灌注后的存活率显著提高至80%(P < 0.01),热疗灌注后的存活率提高至40%(P < 0.05)。灌注后对动物至少随访21天,结果显示肝脏组织学正常,dmPGE2处理的大鼠在灌注后24小时SGOT和SGPT水平显著降低。按上述方式给予dmPGE2(2微克/千克,皮下注射)可延长存活时间,但最终死亡率未显著改善。口服给药(灌注前30分钟、灌注后6小时和24小时,50微克/千克,口服)和治疗后给药(灌注后1小时、6小时和24小时,10微克/千克,皮下注射)对存活无显著影响。在分离的热化疗肝脏灌注后,部分肝切除后的肝再生能力受到严重抑制。用dmPGE2(10微克/千克,皮下注射)预处理可使灌注大鼠的DNA合成反应恢复至部分肝切除后正常对照大鼠的水平(P < 0.05和P < 0.01)。这些研究结果进一步证实了dmPGE2作为肝细胞保护剂的作用,并提示其在对肝脏进行有意的治疗性损伤的情况下具有潜在的临床应用价值。